Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | President & COO | July 24, 2018 | July 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date July 24, 2018 · Filed July 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,155 |
Ending reported balance
After 2018-07-24 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-07-24 · Exercise / conversion · Acquired 5,474 · Balance 27,553 Row 2 · 2018-07-24 · Exercise / conversion · Acquired 8,375 · Balance 35,928 Row 3 · 2018-07-24 · Sale · Disposed 18,773 · Balance 17,155 F1: This sale occurred pursuant to a 10b5-1 Trading Plan. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-02-28 | Direct | 0 |
Reported balance
After 2018-07-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-24 · Exercise / conversion · Disposed 5,474 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.70 · Expires 2021-02-26 | Direct | 16,749 |
Reported balance
After 2018-07-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-07-24 · Exercise / conversion · Disposed 8,375 · Balance 16,749 |
| Common StockSEC Table I · non-derivative | IndirectBy Revocable Trust | 40,748 |
Reported balance
Holding disclosure · report date 2018-07-24 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 40,748 |
Filing footnotes · ownership attribution and instrument terms
F1: This sale occurred pursuant to a 10b5-1 Trading Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2018 Filed Jul 25, 2018 22:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 8,375 | $0.00 Strike: $73.70 | $0.00 |
DisclosureSEC source: 0001127602-18-023857 · form4.xml · derivative · entry 6 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,749 Underlying: Common Stock · 8,375 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 22:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,474 | $0.00 Strike: $59.41 | $0.00 |
DisclosureSEC source: 0001127602-18-023857 · form4.xml · derivative · entry 5 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,474 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 22:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 18,773 | $125.00 | $2,346,625.00 |
DisclosureSEC source: 0001127602-18-023857 · form4.xml · nonDerivative · entry 3 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,155 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 22:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 8,375 | $73.70 | $617,237.50 |
DisclosureSEC source: 0001127602-18-023857 · form4.xml · nonDerivative · entry 2 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 22:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 5,474 | $59.41 | $325,210.34 |
DisclosureSEC source: 0001127602-18-023857 · form4.xml · nonDerivative · entry 1 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 22:36 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 11,600 | $125.00 | $1,450,000.00 |
DisclosureSEC source: 0001127602-18-023803 · form4.xml · nonDerivative · entry 1 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,079 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 12:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,165 | $0.00 Strike: $76.67 | $0.00 |
DisclosureSEC source: 0001127602-18-023565 · form4.xml · derivative · entry 4 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,165 Underlying: Common Stock · 6,165 shares Expires 2020-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 12:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 11,126 | $120.00 | $1,335,120.00 |
DisclosureSEC source: 0001127602-18-023565 · form4.xml · nonDerivative · entry 2 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,679 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · balance_after: On 3/08/2018: 3,514 shares were transferred from Direct Holdings to the Revocable Trust. On 6/05/2018: 21,485 shares were transferred from the Revocable Trust to Direct Holdings. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 12:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 6,165 | $76.67 | $472,670.55 |
DisclosureSEC source: 0001127602-18-023565 · form4.xml · nonDerivative · entry 1 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 11:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 605 | $107.82 | $65,231.10 |
DisclosureSEC source: 0001127602-18-009467 · form4.xml · nonDerivative · entry 1 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,669 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 21:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 621 | $108.95 | $67,657.95 |
DisclosureSEC source: 0001127602-18-009085 · form4.xml · nonDerivative · entry 1 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,274 Read SEC document |
| February 26, 2018 Filed Feb 26, 2018 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 759 | $109.34 | $82,989.06 |
DisclosureSEC source: 0001127602-18-008366 · form4.xml · nonDerivative · entry 3 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,895 F2 · balance_after: On 2/1/2018, 11,702 shares were transferred from Direct Holdings to the Revocable Trust. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 805 | $109.34 | $88,018.70 |
DisclosureSEC source: 0001127602-18-008366 · form4.xml · nonDerivative · entry 2 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,654 Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 31,191 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-18-008366 · form4.xml · derivative · entry 5 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,191 Underlying: Common Stock · 31,191 shares Expires 2023-02-23 F4 · derivative.exercise_date: Stock options vest as follows: 7,797 options vest one (1) year from the date of grant, 7,798 options vest two (2) years from the date of grant, 7,798 options vest three (3) years from the date of grant, and 7,798 options vest four (4) years from the date of grant. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 6,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008366 · form4.xml · nonDerivative · entry 1 Molho Davide · CIK 0001507332 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,459 F1 · security: Consists of 6,910 unvested restricted stock units that vest as follows: 1,727 shares vest one (1) year from the date of issuance, 1,728 shares vest two (2) years from the date of issuance, 1,727 shares vest three (3) years from the date of issuance, and 1,728 shares vest four (4) years from the date of issuance. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 19:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 6,902 | $106.97 | $738,306.94 |
DisclosureSEC source: 0001127602-18-002636 · form4.xml · nonDerivative · entry 2 Molho Davide · CIK 0001507332 · Corporate EVP & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,251 Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 19:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 18,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-002636 · form4.xml · nonDerivative · entry 1 Molho Davide · CIK 0001507332 · Corporate EVP & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,153 F1 · kind: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 27, 2015. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,165 | $0.00 Strike: $76.67 | $0.00 |
DisclosureSEC source: 0001127602-17-029530 · form4.xml · derivative · entry 4 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,330 Underlying: Common Stock · 6,165 shares Expires 2020-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6,165 | $110.00 | $678,150.00 |
DisclosureSEC source: 0001127602-17-029530 · form4.xml · nonDerivative · entry 2 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,549 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 6,165 | $76.67 | $472,670.55 |
DisclosureSEC source: 0001127602-17-029530 · form4.xml · nonDerivative · entry 1 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.60 | $10,860.00 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 11 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,549 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $108.56 | $32,568.00 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 10 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,649 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $108.55 | $21,710.00 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 9 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,949 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.55 | $10,854.50 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 8 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,149 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.53 | $10,852.50 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 7 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,249 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.43 | $10,843.00 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 6 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,349 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 600 | $108.41 | $65,043.00 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 5 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,449 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 467 | $108.40 | $50,620.47 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 4 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,049 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 201 | $108.36 | $21,780.36 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 3 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,516 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $108.34 | $43,334.00 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 2 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,717 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.31 | $10,831.00 |
DisclosureSEC source: 0001127602-17-027116 · form4.xml · nonDerivative · entry 1 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,117 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $108.26 | $32,478.00 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 29 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,217 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $108.24 | $21,648.00 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 28 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,517 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.18 | $10,818.00 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 27 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,717 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $108.16 | $21,632.00 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 26 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,817 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 36 | $108.13 | $3,892.68 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 25 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,017 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4 | $108.13 | $432.50 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 24 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,053 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.12 | $10,812.00 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 23 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,057 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.11 | $10,811.00 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 22 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,157 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6 | $108.11 | $648.63 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 21 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,257 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.10 | $10,810.00 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 20 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,263 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $108.09 | $54,045.00 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 19 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,363 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.08 | $10,807.50 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 18 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,863 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $108.07 | $21,613.00 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 17 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,963 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,104 | $108.06 | $119,298.24 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 16 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,163 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.06 | $10,805.50 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 15 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,267 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 22 | $108.04 | $2,376.88 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 14 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,367 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $108.03 | $54,015.00 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 13 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,389 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $108.03 | $10,802.50 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 12 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,889 Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 12:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 207 | $108.02 | $22,360.14 |
DisclosureSEC source: 0001127602-17-027114 · form4.xml · nonDerivative · entry 11 Molho Davide · CIK 0001507332 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,989 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.